Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Cancer has myriad effects on metabolism that include both rewiring of intracellular
metabolism to enable cancer cells to proliferate inappropriately and adapt to the tumor …

The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and
progression are being increasingly defined. The TRACERx Renal studies and others that …

Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …

Diminished oxygen availability, termed hypoxia, within solid tumors is one of the most
common characteristics of cancer. Hypoxia shapes the landscape of the tumor …

The TANK-binding kinase 1 (TBK1) is a serine/threonine kinase belonging to the non-
canonical inhibitor of nuclear factor-κB (IκB) kinase (IKK) family. TBK1 can be activated by …

Hypoxia, a common feature of solid tumors, greatly hinders the efficacy of conventional
cancer treatments such as chemo-, radio-, and immunotherapy. The depletion of oxygen in …

The inhibitor of kappa B kinase (IKK) family consists of IKKα, IKKβ, and the IKK-related
kinases TBK1 and IKKε. These kinases are considered master regulators of inflammation …

Loss of the von Hippel–Lindau (VHL) tumor suppressor is a hallmark feature of renal clear
cell carcinoma. VHL inactivation results in the constitutive activation of the hypoxia-inducible …

The success of precision oncology—which aims to match the right therapies to the right
patients based on molecular status—is predicated on a robust pipeline of molecular targets …